VA-CTA
3.10.2018 22:02:11 CEST | Business Wire | Press release
The Consumer Technology Association (CTA)TM hosted the sixth annual CES Unveiled Paris today, making several announcements and shining a spotlight on the latest tech innovation. Co-located for the first time with the Mondial Paris Motor Show , CES Unveiled Paris gathered innovative exhibitors, media and industry professionals to experience the latest tech trends and products expected at CES® 2019 that will change our world for the better. Owned and produced by CTA, CES 2019 will run January 8-11, 2019 in Las Vegas, Nevada.
During the event, CTA Executive Vice President of CES Karen Chupka announced 55 French companies selected as CES® 2019 Innovation Honorees . Selected Honorees included GEOFLEX in the vehicle intelligence and self-driving category and Pixminds honored in the gaming category.
“CES Unveiled Paris highlights the innovative spirit fueling Europe’s dynamic tech market, and the French companies recognized as this year’s CES Innovation Award honorees represent the future of technology,” said Chupka. “The products and services honored today reflect the ingenuity driving our industry forward and improving the way we live, work and play.”
The remaining Innovation honorees will be announced at CES Unveiled New York on November 8, 2018. The full list of Honorees will be posted online at CES.tech and showcased at CES 2019, January 8-11.
CTA President and CEO Gary Shapiro also announced today that Dr. Lisa Su, president and CEO of AMD, will deliver a keynote at CES 2019. Dr. Su joins IBM CEO Ginni Rometty as confirmed CES 2019 keynote speakers, with additional speakers to be announced in the coming weeks.
Showcasing the latest technology products and celebrating European innovation, CES Unveiled Paris was the largest event since its inaugural debut in 2013. The event hosted 1,051 attendees from 44 countries and regions, and featured more than 76 exhibitors.
Now a full-day event, and in collaboration with the Connecting Leaders Club, CES Unveiled Paris debuted the Executive Forum on Innovation, with programming focused on emerging trends including mobility, energy and environment and artificial intelligence. More than 20 speakers were featured, including executives from Axa, Accenture, Google, Salesforce and Valeo, as they discussed the future of innovation, including trends expected at CES this January.
CES 2019 is the world’s most important and influential event. The 2019 event will showcase life-changing technology across every major industry, featuring 4,500 exhibitors across 2.75M net square feet (260K net square meters) of exhibit space. CES provides access to the very latest transformative tech such as 5G connectivity, artificial intelligence, augmented and virtual reality, smart home, smart cities, sports, machine intelligence and more.
CES is also one of the largest displays of vehicle technology in the world and was recently named as USA Today’s 10 Best Auto Shows. The 2019 show will feature more than 150 vehicle tech companies, including eight automakers, featuring the latest concept cars and connected vehicles.
Areas new to CES 2019 include the Tourism Marketplace, as well as the recently announced Resilience area, focused on technologies that keep the world healthy, safe, warm, fed and secure in the face of adversity.
Registration for CES 2019 is now open. For the latest exhibitor news and show announcements, visit CES.tech .
High-definition video b-roll of CES is available for easy download on CESbroll.com . See exclusive photos from the CES show floor, keynotes, conference sessions, events and award ceremonies in the CES photo gallery .
About CES:
CES® is the world's gathering place for all who thrive on the business of consumer technologies. It has served as the proving ground for innovators and breakthrough technologies for 50 years-the global stage where next-generation innovations are introduced to the marketplace. As the largest hands-on event of its kind, CES features all aspects of the industry. Owned and produced by the Consumer Technology Association (CTA)TM , it attracts the world's business leaders and pioneering thinkers. Check out CES video highlights . Follow CES online at CES.tech and on social .
About Consumer Technology Association:
Consumer Technology Association (CTA)™ is the trade association representing the $377 billion U.S. consumer technology industry, which supports more than 15 million U.S. jobs. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best-known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. CTA also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.
UPCOMING EVENTS
-
Innovate
Celebrate
- Register
October 15-17, Boston, MA -
CES
Unveiled New York
November 8, New York, NY -
CES
Unveiled Las Vegas
January 6, Las Vegas, NV -
CES
2019
- Register
January 8-11, Las Vegas, NV -
CES
Asia 2019
June 11-13, Shanghai, China
View source version on businesswire.com: https://www.businesswire.com/news/home/20181003005856/en/
Contact:
Consumer Technology Association Teresa Hsu, 703-907-5259 thsu@CTA.tech www.CES.tech or Justin Siraj, 703-907-7415 jsiraj@CTA.tech www.CES.tech
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom